Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Immuron Limited ( (AU:IMC) ) just unveiled an announcement.
Immuron Limited reported a 48.6% increase in revenue to $7.29 million for the year ended June 30, 2025, driven by strong sales of its Travelan product in Australia and North America. Despite a reduction in losses by 24.3% to $5.25 million, the company’s cash position decreased significantly to $2.83 million from the previous year. The company anticipates continued revenue growth from Travelan, although no dividends were declared for the year.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases. Its primary product, Travelan, is aimed at preventing travelers’ diarrhea, with significant sales in the Australian and North American markets.
Average Trading Volume: 179,959
Technical Sentiment Signal: Sell
Current Market Cap: A$18.24M
Learn more about IMC stock on TipRanks’ Stock Analysis page.